Ability of lymphokine-activated killer cells to lyse mycobacteria-infected cells.
Lymphokine-activated killer (LAK) cells were generated by interleukin-2 activation of peripheral blood lymphocytes obtained from lepromatous leprosy (LL) patients and healthy individuals. The ability of LAK cells to lyse targets (macrophages and T-24, a bladder carcinoma cell line) infected with mycobacteria (Mycobacterium leprae and mycobacterial strain ICRC) was assessed in a 51 chromium-release assay. It was observed that LAK cells generated from LL patients and healthy individuals could preferentially lyse M. leprae or ICRC-pulsed macrophages and T-24 cells, compared to non-pulsed targets. The ability of LAK cells to kill intracellular mycobacteria was demonstrated in colony forming assays. These results indicate a promising role for LAK cells in immunotherapy of leprosy.
Chiplunkar
S V
SV
Cellular Immunology Division, Cancer Research Institute, Tata Memorial Centre, Bombay, India.
Deshmukh
M A
MA
Kode
J A
JA
Gangal
S G
SG
Deo
M G
MG
D002277:Carcinoma / Q000473:pathology; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D015440:Leprosy, Lepromatous / Q000276:immunology* / Q000473:pathology; D008264:Macrophages / Q000382:microbiology*; D009166:Mycobacterium leprae / Q000276:immunology*; D014411:Neoplastic Stem Cells / Q000382:microbiology*; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000473:pathology
D007376:Interleukin-2